Waters introduces BioResolve Protein A Affinity Columns to accelerate antibody titer measurement, enhancing process agility and batch quality

Waters Corporation today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements.

Continue ReadingWaters introduces BioResolve Protein A Affinity Columns to accelerate antibody titer measurement, enhancing process agility and batch quality

Fujifilm rebrands Life Sciences Companies to strengthen position as strategic partners for life, offering end-to-end solutions

FUJIFILM Corporation's Life Sciences Group companies, a portfolio of businesses offering products, services and comprehensive solutions that span all stages of therapeutic development from discovery through to commercialization, today announced…

Continue ReadingFujifilm rebrands Life Sciences Companies to strengthen position as strategic partners for life, offering end-to-end solutions

Health harm warnings found most effective in discouraging e-cigarette use

Electronic-cigarette warnings are effective in discouraging vaping, with warnings specific to health harms being generally more effective than warnings about e-cigarette addiction, according to a meta-analysis of 24 studies conducted…

Continue ReadingHealth harm warnings found most effective in discouraging e-cigarette use

Gaps in surveillance leave European children at risk of acute flaccid myelitis

European researchers surveyed 28 countries and found acute flaccid myelitis (AFM) remains underreported, with only Norway maintaining dedicated surveillance. Most AFM cases coincided with years of high enterovirus D68 (EV-D68)…

Continue ReadingGaps in surveillance leave European children at risk of acute flaccid myelitis

First-in-class antibody-drug conjugate shows high response rates in rare blood cancer trial

The first-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and high response rates for patients with blastic plasmacytoid dendric cell neoplasm (BPDCN), according to data from a Phase…

Continue ReadingFirst-in-class antibody-drug conjugate shows high response rates in rare blood cancer trial